TY - JOUR
T1 - Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats
AU - Kidoguchi, Satoshi
AU - Kitada, Kento
AU - Nakajima, Kazuki
AU - Nakano, Daisuke
AU - Ohsaki, Hiroyuki
AU - Kittikulsuth, Wararat
AU - Kobara, Hideki
AU - Masaki, Tsutomu
AU - Yokoo, Takashi
AU - Takahashi, Kazuo
AU - Titze, Jens
AU - Nishiyama, Akira
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1/15
Y1 - 2022/1/15
N2 - Aims: The number of cancer survivors with cardiovascular disease is increasing. However, the effect of cancer on body fluid regulation remains to be clarified. In this study, we evaluated body osmolyte and water imbalance in rats with hepatocellular carcinoma. Main methods: Wistar rats were administered diethylnitrosamine, a carcinogenic drug, to establish liver cancer. We analyzed tissue osmolyte and water content, and their associations with aldosterone secretion. Key findings: Hepatocellular carcinoma rats had significantly reduced body mass and the amount of total body sodium, potassium, and water. However, these rats had significantly increased relative tissue sodium, potassium, and water content per tissue dry weight. Furthermore, these changes in sodium and water balance in hepatocellular carcinoma rats were significantly associated with increased 24-h urinary aldosterone excretion. Supplementation with 0.25% salt in drinking water improved body weight reduction associated with sodium and water retention in hepatocellular carcinoma rats, which was suppressed by treatment with spironolactone, a mineralocorticoid receptor antagonist. Additionally, the urea-driven water conservation system was activated in hepatocellular carcinoma rats. Significance: These findings suggest that hepatocellular carcinoma induces body mass loss in parallel with activation of the water conservation system including aldosterone secretion and urea accumulation to retain osmolyte and water. The osmolyte and water retention at the tissue level may be a causative factor for ascites and edema formation in liver failure rats.
AB - Aims: The number of cancer survivors with cardiovascular disease is increasing. However, the effect of cancer on body fluid regulation remains to be clarified. In this study, we evaluated body osmolyte and water imbalance in rats with hepatocellular carcinoma. Main methods: Wistar rats were administered diethylnitrosamine, a carcinogenic drug, to establish liver cancer. We analyzed tissue osmolyte and water content, and their associations with aldosterone secretion. Key findings: Hepatocellular carcinoma rats had significantly reduced body mass and the amount of total body sodium, potassium, and water. However, these rats had significantly increased relative tissue sodium, potassium, and water content per tissue dry weight. Furthermore, these changes in sodium and water balance in hepatocellular carcinoma rats were significantly associated with increased 24-h urinary aldosterone excretion. Supplementation with 0.25% salt in drinking water improved body weight reduction associated with sodium and water retention in hepatocellular carcinoma rats, which was suppressed by treatment with spironolactone, a mineralocorticoid receptor antagonist. Additionally, the urea-driven water conservation system was activated in hepatocellular carcinoma rats. Significance: These findings suggest that hepatocellular carcinoma induces body mass loss in parallel with activation of the water conservation system including aldosterone secretion and urea accumulation to retain osmolyte and water. The osmolyte and water retention at the tissue level may be a causative factor for ascites and edema formation in liver failure rats.
KW - Body fluid
KW - Catabolism
KW - Glucocorticoid receptor
KW - Hepatocellular carcinoma
KW - Mineralocorticoid receptor
KW - Water conservation
UR - http://www.scopus.com/inward/record.url?scp=85120740590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120740590&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2021.120192
DO - 10.1016/j.lfs.2021.120192
M3 - Article
C2 - 34871664
AN - SCOPUS:85120740590
SN - 0024-3205
VL - 289
JO - Life Sciences
JF - Life Sciences
M1 - 120192
ER -